Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2013 3
2014 2
2015 4
2016 5
2017 2
2018 4
2019 3
2020 1
2021 2
2022 2
2023 3
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage.
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Anderson CS, et al. N Engl J Med. 2013 Jun 20;368(25):2355-65. doi: 10.1056/NEJMoa1214609. Epub 2013 May 29. N Engl J Med. 2013. PMID: 23713578 Free article. Clinical Trial.
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
Newsome SD, Krzystanek E, Selmaj KW, Dufek M, Goldstick L, Pozzilli C, Figueiredo C, Townsend B, Kletzl H, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Bhullar GD, Schneble HM, Centonze D. Newsome SD, et al. Among authors: schneble hm. Neurology. 2025 May 13;104(9):e213574. doi: 10.1212/WNL.0000000000213574. Epub 2025 Apr 17. Neurology. 2025. PMID: 40245351 Free PMC article. Clinical Trial.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F. Hartung HP, et al. Among authors: schneble hm. Mult Scler. 2022 Mar;28(3):429-440. doi: 10.1177/13524585211024997. Epub 2021 Jul 9. Mult Scler. 2022. PMID: 34240656 Free article. Clinical Trial.
Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.
Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ; international ARUBA investigators. Mohr JP, et al. Lancet. 2014 Feb 15;383(9917):614-21. doi: 10.1016/S0140-6736(13)62302-8. Epub 2013 Nov 20. Lancet. 2014. PMID: 24268105 Free PMC article. Clinical Trial.
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdová EK. Cerqueira JJ, et al. Among authors: schneble hm. Neurology. 2025 Feb 25;104(4):e210142. doi: 10.1212/WNL.0000000000210142. Epub 2025 Jan 30. Neurology. 2025. PMID: 39883906 Free PMC article. Clinical Trial.
Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke.
Chalos V, Venema E, Mulder MJHL, Roozenbeek B, Steyerberg EW, Wermer MJH, Lycklama À Nijeholt GJ, van der Worp HB, Goyal M, Campbell BCV, Muir KW, Guillemin F, Bracard S, White P, Dávalos A, Jovin TG, Hill MD, Mitchell PJ, Demchuk AM, Saver JL, van der Lugt A, Brown S, Dippel DWJ, Lingsma HF; HERMES CollaboratorsMR CLEAN Registry Investigators. Chalos V, et al. JAMA Neurol. 2023 Jul 31;80(9):940-8. doi: 10.1001/jamaneurol.2023.2392. Online ahead of print. JAMA Neurol. 2023. PMID: 37523199 Free PMC article.
COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H. Hughes R, et al. Among authors: schneble hm. Mult Scler Relat Disord. 2021 Apr;49:102725. doi: 10.1016/j.msard.2020.102725. Epub 2020 Dec 30. Mult Scler Relat Disord. 2021. PMID: 33482590 Free PMC article.
Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.
Zuurbier SM, Hickman CR, Tolias CS, Rinkel LA, Leyrer R, Flemming KD, Bervini D, Lanzino G, Wityk RJ, Schneble HM, Sure U, Al-Shahi Salman R; Scottish Audit of Intracranial Vascular Malformations Steering Committee. Zuurbier SM, et al. Among authors: schneble hm. Lancet Neurol. 2019 Oct;18(10):935-941. doi: 10.1016/S1474-4422(19)30231-5. Epub 2019 Aug 7. Lancet Neurol. 2019. PMID: 31401075 Free PMC article.
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
Newsome SD, Krzystanek E, Selmaj KW, Dufek M, Goldstick L, Pozzilli C, Figueiredo C, Townsend B, Kletzl H, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Bhullar GD, Schneble HM, Centonze D. Newsome SD, et al. Among authors: schneble hm. Neurology. 2025 Aug 12;105(3):e213909. doi: 10.1212/WNL.0000000000213909. Epub 2025 Jul 2. Neurology. 2025. PMID: 40601887 Free PMC article. No abstract available.
28 results